ArticleOncotarget2016
Systematic analysis of tumour cell-extracellular matrix adhesion identifies independent prognostic factors in breast cancer.
Article in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Prognostic value of high stanniocalcin 2 expression in solid cancers: A meta-analysis.Medicine · 2019Pooled it
- Peptide-Modified Lipid Nanoparticles Boost the Antitumor Efficacy of RNA Therapeutics.ACS nano · 2025Article
- Cell membrane-anchored and tumor-targeted IL-12 T-cell therapy destroys cancer-associated fibroblasts and disrupts extracellular matrix in heterogenous osteosarcoma xenograft models.Journal for immunotherapy of cancer · 2024Article
- Epigenetic regulation of LINC01270 in breast cancer progression by mediating LAMA2 promoter methylation and MAPK signaling pathway.Cell biology and toxicology · 2023Article
- Integrating Proteomics and Lipidomics for Evaluating the Risk of Breast Cancer Progression: A Pilot Study.Biomedicines · 2023Article
- Article
- Stanniocalcin 2 (STC2): a universal tumour biomarker and a potential therapeutical target.Journal of experimental & clinical cancer research : CR · 2022Review
- Immunohistochemical Expression of Stanniocalcin 2 in Colorectal Cancer: A Retrospective Egyptian Study.Iranian journal of pathology · 2022Article
- Article
- Research progress of STC2 in breast cancer.Biophysics reports · 2021Article
- The Burden of Post-Translational Modification (PTM)-Disrupting Mutations in the Tumor Matrisome.Cancers · 2021Article
- Effects of Sphingosine-1-Phosphate on Cell Viability, Differentiation, and Gene Expression of Adipocytes.International journal of molecular sciences · 2020Article
- The role of extracelluar matrix in osteosarcoma progression and metastasis.Journal of experimental & clinical cancer research : CR · 2020Review
- New Insights Into Physiological and Pathophysiological Functions of Stanniocalcin 2.Frontiers in endocrinology · 2020Review
- Paxillin family of focal adhesion adaptor proteins and regulation of cancer cell invasion.International review of cell and molecular biology · 2020Article
- Pan-Cancer analysis of the expression and regulation of matrisome genes across 32 tumor types.Matrix biology plus · 2019Article
- Upregulation of STC2 in colorectal cancer and its clinicopathological significance.OncoTargets and therapy · 2019Article
- Stanniocalcin 2 expression is associated with a favourable outcome in male breast cancer.The journal of pathology. Clinical research · 2018Article
- Evaluation of CDK12 Protein Expression as a Potential Novel Biomarker for DNA Damage Response-Targeted Therapies in Breast Cancer.Molecular cancer therapeutics · 2018Article
- The proliferation and angiogenesis in hemangioma-derived endothelial cells is affected by STC2 medicated VEGFR2/Akt/eNOS pathway.Pakistan journal of medical sciencesArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
Abstract
Tumour cell-extracellular matrix (ECM) interactions are fundamental for discrete steps in breast cancer progression. In particular, cancer cell adhesion to ECM proteins present in the microenvironment is critical for accelerating tumour growth and facilitating metastatic spread. To assess the utility of tumour cell-ECM adhesion as a means for discovering prognostic factors in breast cancer survival, here we perform a systematic phenotypic screen and characterise the adhesion properties of a panel of human HER2 amplified breast cancer cell lines across six ECM proteins commonly deregulated in breast cancer. We determine a gene expression signature that defines a subset of cell lines displaying impaired adhesion to laminin. Cells with impaired laminin adhesion showed an enrichment in genes associated with cell motility and molecular pathways linked to cytokine signalling and inflammation. Evaluation of this gene set in the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) cohort of 1,964 patients identifies the F12 and STC2 genes as independent prognostic factors for overall survival in breast cancer. Our study demonstrates the potential of in vitro cell adhesion screens as a novel approach for identifying prognostic factors for disease outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.